ResMed director sells 2,000 shares in planned Rule 10b5-1 trade

ResMed Inc. director reports planned stock sale.

Accepted by SEC EDGAR 12/04/2025 - 01:46 PM EST Learn about SEC filing dates

Rhea-AI Filing Summary

ResMed Inc. director reports planned stock sale. A reporting person serving as a director of ResMed Inc. (ticker RMD) sold 2,000 shares of ResMed common stock on 12/03/2025 at a price of $251.47 per share. The transaction was coded as a sale and was made under a Rule 10b5-1 trading plan adopted on August 12, 2025, which allows pre-arranged trades according to preset instructions. Following this sale, the insider directly beneficially owns 68,773 shares of ResMed common stock, reflecting the remaining stake reported in this filing.

Insider Trade Summary

Net Seller: 2,000 shares

Net Sell 1 txn

Insider FARRELL PETER C

Role Director

Sold 2,000 shs ($503K)

Type	Security	Shares	Price	Value
Sale	ResMed Common Stock	2,000	$251.47	$503K

Holdings After Transaction: ResMed Common Stock — 68,773 shares (Direct)

Footnotes (1)

1. F1. The transaction was conducted under a Rule 10b5-1 plan adopted August 12, 2025.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did ResMed (RMD) report in this Form 4?

A ResMed Inc. director reported selling 2,000 shares of ResMed common stock on 12/03/2025, as disclosed in the Form 4.

At what price were the ResMed (RMD) shares sold in the reported transaction?

The 2,000 shares of ResMed common stock were sold at a price of $251.47 per share, according to the transaction table.

How many ResMed (RMD) shares does the insider still own after this sale?

After the reported sale, the insider directly beneficially owns 68,773 shares of ResMed common stock.

Was the ResMed (RMD) insider sale made under a Rule 10b5-1 trading plan?

Yes. The explanation of responses states the transaction was conducted under a Rule 10b5-1 plan adopted on August 12, 2025.

What is the reporting person’s relationship to ResMed (RMD)?

The reporting person is identified as a Director of ResMed Inc., and the signature block shows /s/ Peter C. Farrell, Chairman emeritus.

Is this ResMed (RMD) Form 4 filed by more than one reporting person?

No. The form indicates it is filed by one reporting person, not by more than one reporting person.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

FARRELL PETER C

(Last) (First) (Middle)

9001 SPECTRUM CENTER BLVD.

(Street)

SAN DIEGO CA 92123

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
RESMED INC [ RMD ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
12/03/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
ResMed Common Stock	12/03/2025		S(1)		2,000	D	$251.47	68,773	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The transaction was conducted under a Rule 10b5-1 plan adopted August 12, 2025.

	/s/ Peter C. Farrell, Chairman emeritus	12/04/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.